Literature DB >> 22340366

Screening of the FUS gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin.

Z-Y Zou1, Y Peng, X-H Feng, X-N Wang, Q Sun, M-S Liu, X-G Li, L-Y Cui.   

Abstract

BACKGROUND: According to studies in European, North American, Australian, and Asian populations, FUS gene mutations occur in 0.6-20.2% of the patients with familial amyotrophic lateral sclerosis (ALS) and 0.4-2.0% of sporadic ALS cases. In China, FUS mutations have been reported in several familial ALS pedigrees but not in sporadic ALS cases. Here, we screened for FUS mutations in Chinese patients with ALS.
METHODS: We sequenced all of the 15 exons of FUS in 10 familial ALS pedigrees, exons 5, 6, 14, and 15 in 210 patients with sporadic ALS and 151 healthy controls. All patients were negative for SOD1, TARDBP, and ANG mutations.
RESULTS: A c.1562G>T (p.R521L) missense mutation was identified in one familial ALS proband and her asymptomatic daughter. A c.1562G>A (p.R521H) missense mutation was identified in two patients with sporadic ALS. Three synonymous mutations (c.453C>T, c.648C>T, and c.1464C>T) were detected among four patients with sporadic ALS, and a untranslated region variant (*14C>T) was identified in one familial ALS proband and one patient with sporadic ALS.
CONCLUSIONS: The frequency of FUS mutations is approximately 1.0% in our SOD1-, ANG-, TARDBP-mutation-negative sporadic ALS cohort and similar to that reported in previous studies from Asia in our familial ALS cohort. [Correction added on 31 May 2012, after first online publication: the gene FUS- was changed to ANG-]. Our findings provide an overview of the occurrence of FUS mutations in Chinese sporadic and familial ALS cases and highlight the importance of screening for FUS mutations in ALS patients of Chinese origin.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340366     DOI: 10.1111/j.1468-1331.2012.03662.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

2.  The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation.

Authors:  Xinxiu Liu; Jiayu Chen; Wenchao Liu; Xiaogang Li; Qi Chen; Tao Liu; Shaorong Gao; Min Deng
Journal:  Neurogenetics       Date:  2015-04-26       Impact factor: 2.660

Review 3.  Emerging Roles for Phase Separation of RNA-Binding Proteins in Cellular Pathology of ALS.

Authors:  Katarina Milicevic; Branislava Rankovic; Pavle R Andjus; Danijela Bataveljic; Dragomir Milovanovic
Journal:  Front Cell Dev Biol       Date:  2022-02-17

4.  ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules.

Authors:  Caroline Vance; Emma L Scotter; Agnes L Nishimura; Claire Troakes; Jacqueline C Mitchell; Claudia Kathe; Hazel Urwin; Catherine Manser; Christopher C Miller; Tibor Hortobágyi; Mike Dragunow; Boris Rogelj; Christopher E Shaw
Journal:  Hum Mol Genet       Date:  2013-03-07       Impact factor: 6.150

5.  Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.

Authors:  Lihua Hou; Bin Jiao; Tingting Xiao; Lu Zhou; Zhifan Zhou; Juan Du; Xinxiang Yan; Junling Wang; Beisha Tang; Lu Shen
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

6.  The FUS gene is dual-coding with both proteins contributing to FUS-mediated toxicity.

Authors:  Marie A Brunet; Jean-Francois Jacques; Sonya Nassari; Giulia E Tyzack; Philip McGoldrick; Lorne Zinman; Steve Jean; Janice Robertson; Rickie Patani; Xavier Roucou
Journal:  EMBO Rep       Date:  2020-11-23       Impact factor: 9.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.